Aktis Oncology, Inc.
NASDAQ:AKTSBiotechnology
+$0.11 today
- Market cap
- $865.32M
- Beta
- 1.10
- P/E (TTM)
- -28.7
- EPS (TTM)
- -$0.82
Volume 0.44M
Average 0.33M
AKTS Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
Aktis Oncology, Inc.NASDAQ: AKTS
Net Debt · Q1 FY2026 · quarter ended Mar 2026
Net debt of -$360.05M in Q1 FY2026
Q1 FY2026 net debt was -$360.05M.
Context
- Net debt amounted to 62.4% of total assets at the end of Q1 FY2026.
- Net debt grew in size in 2 of the last 3 fiscal years.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (26.24M) USD
- Year-over-year change
- -4.3%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (26.24M) | -4.3% |
| FY2024 | 2024-12-31 | (25.15M) | -56.1% |
| FY2023 | 2023-12-31 | (16.11M) | +87.3% |
| FY2022 | 2022-12-31 | (126.82M) | — |
Net Debt vs competitors
How AKTS compares with its peers on the latest reported figures
- AKTS's Mar 2026 net debt of -$360.05M is the 5th highest of the 6 companies compared; the peer median is -$67.8M.
- Net debt amounts to 62.4% of total assets for AKTS, versus a peer median of 40.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | -$16.99M | +60.3% | — | 1.6% | |
| Mar 2026 | -$30.01M | +72.2% | — | 13.8% | |
| Mar 2026 | -$67.8M | -242.7% | — | 49.2% | |
| Sep 2026 | -$202.58M | +24.6% | — | 40.1% | |
| Mar 2026 | -$360.05M | — | — | 62.4% | |
| Mar 2026 | -$544.14M | +30.6% | — | 83.4% | |
| Peer median (excluding AKTS) | -$67.8M | +30.6% | — | 40.1% | |
Competitors are the stored peer set for AKTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Aktis Oncology, Inc.
NASDAQ:AKTS
Intrinsic Alpha fair value
Locked
Current Price
$16.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.